

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Snyder *et al.*

Serial No.: 10/023,603

Filed: December 17, 2001

For: Nonpeptide Agonists and Antagonists of Vasopressin Receptors

Commissioner for Patents
Washington, DC 20231

Group Art Unit: 1646

January 9, 2003


TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed as well as the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,


Hoang M. Vo
Registration No. 47,158

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)
404-572-5145 (Facsimile)




ney Docket No. 18085.105029 (EMU20030000)

RECEIVED
JAN 14 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.


Sally Sexton

Date: January 9, 2003

Please type a plus sign (+) inside this box → ☐

JAN 13 2003

Approved for use through 10/31/2004. OMB 0651-0041
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/023,603
Filing Date	December 17, 2001
First Named Inventor	Snyder <i>et al.</i>
Group Art Unit	1646
Examiner Name	N/A
Attorney Docket Number	18085.105229 (EMU2090US)

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AA	WO	95/14025		Merck & Co.	26-05-1995		
	AB	WO	95/02587		Merck & Co.	26-01-1995		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AC	CHAABAN, <i>Scientia Pharmaceutica</i> , vol. 48, no. 4, 1980, 356-65, abstract no. 94:150965 CAS.	
	AD	DAI, <i>J. of Organic Chemistry</i> , vol. 63, no. 8, 1998, pp. 2597-2600, abstract no. 128:321740 CAS.	
	AE	DEVGAN, <i>J. of Indian Chem. Society</i> , vol. 44, no. 9, 1967, 776-779, abstract no. 68:95475, CAS.	
	AF	KIRMSE, <i>Chemische Berichte</i> , vol. 105, no. 8, 1972, pp.2746-2753, abstract no. 126850, CAS.	
	AG	KIRMSE, <i>Angewandte Chemie</i> , vol. 9, no. 2, 1970, pp. 165-166, abstract no. 72:100129 CAS.	
	AH	SHIMADA, <i>Chemistry Letters</i> , no. 6, 1998, pp. 513-514, abstract no. 129:149031, CAS.	
	AI	UTLEY, <i>Electroorganic Synthesis</i> , 1991, 377-386, abstract no. 116:129277, CAS.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.